Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Learn what collagen is, why it may or may not have benefits for psoriasis, according to experts, and what the research has found so far.

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Incorporating weight-loss interventions improved psoriasis severity and quality of life for patients with overweight or obesity, according to a systematic review and meta-analysis.Approximately 80% of ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...

A systematic review and meta-analysis finds that weight-loss interventions are associated with decreased psoriasis severity ...

Researchers have found in a new study that in a real-world Japanese cohort, deucravacitinib 6 mg provided sustained disease ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...